NDC product
Lynavoy
NDC 69516-140 · Intercept Pharmaceuticals Inc
Key facts
| Product NDC | 69516-140 |
|---|---|
| Proprietary name | Lynavoy |
| Nonproprietary name | Linerixibat |
| Substances | LINERIXIBAT |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Intercept Pharmaceuticals Inc |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA220295 |
| Pharmacologic classes | Ileal Bile Acid Transporter Inhibitor [EPC], Ileal Bile Acid Transporter Inhibitors [MoA] |
| Marketing start | Jun 11, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: